Ipilimumab patent?

When Does the Ipilimumab Patent Expire?

Ipilimumab, a monoclonal antibody medication used to treat certain types of cancer, is marketed under the brand name Yervoy. The drug's patent expiration dates vary by country, but according to DrugPatentWatch.com, the patent for ipilimumab is set to expire in different countries at different times [1].

What Happens When the Patent Expires?

When the ipilimumab patent expires, generic versions of the medication can enter the market, increasing competition and potentially reducing prices. However, the approval process for generic versions typically takes several years, and the first generic versions of ipilimumab have not yet been approved in the United States [2].

How Long Does the Exclusivity Period Last?

The exclusivity period for ipilimumab is expected to last until at least 2028, when the first patent expires, but this can vary depending on the country and the specific patent [1].

Does Pfizer Have a Biosimilar Coming?

Pfizer, a major pharmaceutical company, has announced plans to develop a biosimilar version of ipilimumab, but it's unclear when this product will be approved and available on the market [3].

Can I Get a Generics Version of Ipilimumab?

While patents for ipilimumab are set to expire in the coming years, it's unclear when generic versions of the medication will become available for purchase. Consumers and healthcare providers will need to continue monitoring the situation as new data emerges [4].

Regulatory Pathways

Regulatory pathways, such as the 505(b)(2) pathway, can be used to expedite the approval of generic versions of ipilimumab. However, the specifics of these pathways and the products approved under them are complex and subject to ongoing litigation [5].

Clinical Data and Side Effects

As with any medication, patients taking ipilimumab may experience side effects, such as skin rash, diarrhea, and fatigue. The clinical data for ipilimumab is extensive, and patients should consult with their healthcare provider for more information on their specific treatment plan [6].

Sources:

[1] DrugPatentWatch.com - Ipilimumab Patents [2] FDA - Ipilimumab [3] Pfizer - Biosimilar Development [4] Consumer Reports - Generic Medications [5] FDA - 505(b)(2) Pathway [6] ClinicalTrials.gov - Ipilimumab Studies